Biphenotypic Sinonasal Sarcoma: Case Reports of Diagnostic Findings and Clinical Management of 3 Cases.

Autor:	Augustin Y; Royal Marsden NHS Foundation Trust, London, U.K.; Yolanda.augustin@rmh.nhs.uk., Zaidi S; Royal Marsden NHS Foundation Trust, London, U.K.; Institute of Cancer Research, London, U.K., Jones RL; Royal Marsden NHS Foundation Trust, London, U.K.; Institute of Cancer Research, London, U.K., Benson C; Royal Marsden NHS Foundation Trust, London, U.K.; Institute of Cancer Research, London, U.K., Simcock R; Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, U.K., Fisher C; University Hospitals Birmingham NHS Foundation Trust, Birmingham, U.K., Thway K; Royal Marsden NHS Foundation Trust, London, U.K.; Institute of Cancer Research, London, U.K., Hallin M; Royal Marsden NHS Foundation Trust, London, U.K., Miah AB; Royal Marsden NHS Foundation Trust, London, U.K.; Institute of Cancer Research, London, U.K.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2023 Apr; Vol. 43 (4), pp. 1581-1589.
DOI:	10.21873/anticanres.16308
Abstrakt:	Background: Biphenotypic sinonasal sarcoma (BSNS) is a rare spindle cell sarcoma distinctly arising in the sinonasal area, with dual myogenic and neural differentiation, and characterised by the presence of PAX3 gene fusion, typically with MAML3. Although the majority may be indolent, up to 25% of cases reported in the literature are locally aggressive, with invasion of adjacent critical structures in the head and neck region. Case Report: We report 3 cases of BSNS reviewed at our institution between 2016-2020 in addition to the current literature. Patient 1 underwent surgery followed by adjuvant radiotherapy but relapsed 24 months later and was not fit for systemic anticancer therapy and managed with palliative care. Due to comorbidities, patient 2 was recommended for active surveillance, with a view to intervening with radiotherapy should there be evidence of clinical progression. At 60 months, the nasal cavity mass remained stable on serial imaging. Patient 3 underwent primary surgical R0 resection and was offered adjuvant post operative radiotherapy 60 Gy/30 fractions/6 weeks but opted for active surveillance and has no clinical or radiological evidence of recurrence 22 months after surgery. Conclusion: The primary management for BSNS is surgical resection. We recommend discussing the role of postoperative adjuvant radiotherapy 60 Gy/30 fractions/6 weeks in patients who are fit for treatment. In clinical practice, dose levels will be constrained by surrounding normal tissues. At present, the role of systemic anticancer therapy is undefined. A prospective registry of ultra-rare cases may provide an evidence base with which to select optimal treatment strategies for BSNS in the future. (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu